Showing results (71-80 of 155) with videos related to
Sort By:
Pageof 16
American Journal of Nephrology|February 7, 2017
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney DiseaseVicente E Torres, Olivier Devuyst, Arlene B Chapman, et al.Kidney International Reports|April 29, 2021
Per-Treatment <i>Post Hoc</i> Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKDAndrew J Mallett, Ronald D Perrone, Gopala Rangan, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 5, 2011
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney diseaseKevin S Heffernan, Jeffrey T Kuvin, Mark J Sarnak, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 6, 2017
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 TrialVicente E Torres, Arlene B Chapman, Olivier Devuyst, et al.Kidney International|December 22, 2004
The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney diseaseTazeen H Jafar, Paul C Stark, Christopher H Schmid, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 8, 2014
Performance of creatinine-based GFR estimating equations in solid-organ transplant recipientsKamran Shaffi, Katrin Uhlig, Ronald D Perrone, et al.Annals of Internal Medicine|July 16, 2003
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratificationAndrew S Levey, Josef Coresh, Ethan Balk, et al.Journal of the American Society of Nephrology : JASN|December 7, 2016
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 TrialOlivier Devuyst, Arlene B Chapman, Ron T Gansevoort, et al.The American Journal of Physiology|June 1, 1994
Regulation of intracellular pH by immortalized human intrahepatic biliary epithelial cell linesS A Grubman, R D Perrone, D W Lee, et al.Kidney Medicine|November 10, 2025
Qualitative Analysis and Comparison of Externally Led Patient-Focused Drug Development Concepts for Autosomal Recessive Polycystic Kidney Disease Against SONG InitiativesBelle Soyfer, Sorin Fedeles, Wendy Ruyle, et al.Pageof 16